Shaw Elana, Wuest William M
Department of Chemistry , Emory University , 1515 Dickey Drive , Atlanta , Georgia 30322 , USA . Email:
Emory Antibiotic Resistance Center , Emory University School of Medicine , 201 Dowman Drive , Atlanta , Georgia 30322 , USA.
RSC Med Chem. 2020 Feb 19;11(3):358-369. doi: 10.1039/c9md00566h. eCollection 2020 Mar 1.
The World Health Organization considers the discovery of new treatments for a top priority. Virulence attenuating combination therapy (VACT) is a pragmatic strategy to improve bacterial clearance, repurpose outmoded antibiotics, improve drug efficacy at lower doses, and reduce the evolution of resistance. and studies have shown that adding a quorum sensing inhibitor or an extracellular polymeric substance repressor to classical antibiotics synergistically improves antipseudomonal activity. This review highlights why VACT could specifically benefit cystic fibrosis patients harboring chronic infections, outlines the current landscape of synergistic combinations between virulence-targeting small-molecules and anti-pseudomonal drugs, and suggests future directions for VACT research.
世界卫生组织将发现新的治疗方法视为首要任务。减毒联合疗法（VACT）是一种切实可行的策略，可提高细菌清除率、重新利用过时的抗生素、在较低剂量下提高药物疗效并减少耐药性的产生。并且研究表明，在传统抗生素中添加群体感应抑制剂或细胞外聚合物阻遏物可协同提高抗假单胞菌活性。本综述强调了VACT为何能特别惠及患有慢性感染的囊性纤维化患者，概述了靶向毒力的小分子与抗假单胞菌药物之间协同组合的现状，并提出了VACT研究的未来方向。
